(VIANEWS) – KBC ANCORA (KBCA.BR), SANOFI (SAN.PA), AXA (CS.PA) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up until now. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. KBC ANCORA (KBCA.BR)
85.39% Payout Ratio
KBC Ancora SCA holds participating interest in KBC Group SA. The company was formerly known as Almancora SCA and changed its name to KBC Ancora SCA in June 2007. KBC Ancora SCA was incorporated in 1998 and is based in Leuven, Belgium. KBC Ancora SCA is a subsidiary of Cera SC.
Earnings Per Share
As for profitability, KBC ANCORA has a trailing twelve months EPS of €10.29.
PE Ratio
KBC ANCORA has a trailing twelve months price to earnings ratio of 3.73. Meaning, the purchaser of the share is investing €3.73 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.98%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 6, 2023, the estimated forward annual dividend rate is 9.8 and the estimated forward annual dividend yield is 24.75%.
Yearly Top and Bottom Value
KBC ANCORA’s stock is valued at €38.42 at 07:10 EST, way under its 52-week high of €49.88 and way higher than its 52-week low of €32.08.
Moving Average
KBC ANCORA’s value is below its 50-day moving average of €41.30 and way below its 200-day moving average of €43.15.
More news about KBC ANCORA.
2. SANOFI (SAN.PA)
51.97% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.85.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.54. Meaning, the purchaser of the share is investing €14.54 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.07%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 3.56 and the estimated forward annual dividend yield is 3.47%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SANOFI’s EBITDA is 3.07.
Moving Average
SANOFI’s value is higher than its 50-day moving average of €98.16 and above its 200-day moving average of €95.17.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.4%, now sitting on 46.04B for the twelve trailing months.
More news about SANOFI.
3. AXA (CS.PA)
50.66% Payout Ratio
AXA SA, through its subsidiaries, provides insurance, asset management, and banking services worldwide. The company operates through six segments: France, Europe, Asia, AXA XL, International, and Transversal & Central Holdings. It offers life and savings insurance products, such as savings and retirement, other health, and personal protection products. The company also provides property and casualty insurance products, including car, home, and personal or professional liability to individual and business clients; international insurance for large corporate clients in Europe; and marine and aviation insurance services, as well as property and casualty reinsurance products. In addition, it offers asset management services in the areas of various asset classes, including equities, bonds, hedge funds, private equity, and real estate for the group's insurance companies and their clients, and retail and institutional clients. Further, the company provides health, term life, whole life, universal life, endowment, and other investment-based products for personal/individual and commercial/ group customers. AXA SA was founded in 1852 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, AXA has a trailing twelve months EPS of €2.88.
PE Ratio
AXA has a trailing twelve months price to earnings ratio of 9.96. Meaning, the purchaser of the share is investing €9.96 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.69%.
Volume
Today’s last reported volume for AXA is 677743 which is 78.22% below its average volume of 3112430.
More news about AXA.
4. IMCD (IMCD.AS)
46.84% Payout Ratio
IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company offers bioactives, biocides, chelates, functional additives, rheology modifiers, silicones, solubilisers, and solvents; active pharmaceutical, agrochemicals, biopharma, excipients and formulation, nutraceuticals, and regulated synthesis; actives, UV sunscreens, rheology modifiers, thickeners, surfactants, emulsifiers, emollients, elastomers, humectants, waxes, film formers, functional powders, hair styling polymers, hair conditioners, solvents, solubilizers, pigments, pearls, colorants, opacifiers, pearlisers, preservatives, antioxidants, additives, fragrances, and essential oils; and resins and binders, additives, functional fillers, and specialty solvents. It also provides taste, texture, nutrition, and function; base oil, fuel addictive, lubricants addictive, lubricants finished fluids, solvents, degreasers and fuel, compounds, and upstream, midstream and downstream oil, gas and energy; bio-based chemicals, binders, corrosion inhibitors, catalysts, intermediates, monomers, organic building blocks, processing aids, reactive diluents, solvents, and surfactants. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.
Earnings Per Share
As for profitability, IMCD has a trailing twelve months EPS of €5.07.
PE Ratio
IMCD has a trailing twelve months price to earnings ratio of 23.42. Meaning, the purchaser of the share is investing €23.42 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.66%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 28, 2023, the estimated forward annual dividend rate is 2.37 and the estimated forward annual dividend yield is 1.91%.
Sales Growth
IMCD’s sales growth is 7.2% for the ongoing quarter and 1% for the next.
Volume
Today’s last reported volume for IMCD is 24497 which is 77.59% below its average volume of 109354.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.3%, now sitting on 4.59B for the twelve trailing months.
More news about IMCD.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1’s stock is considered to be overbought (>=80).
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1% and 1%, respectively.
More news about 1.
